Monoclonal antibodies (or mAbs) are a critical tool in fighting the COVID-19 pandemic, and the U.S. Department of Health and Human Services (HHS) is committed to fair and equitable access to these important products. A surge in the Delta variant coupled with low vaccination rates in certain areas of the country contributed to an increase in COVID-19 over the July-August timeframe.
As a result, the HHS Office of the Assistant Secretary for Preparedness and Response (HHS/ASPR) implemented a State and Territory-Coordinated Distribution System for mAbs on September 13, 2021, similar to the process used from November 2020 to February 2021.
|
Questions? If you have questions about the new state/territory coordinated distribution system, check out our frequently asked questions section. View All FAQs >> |